;PMID: 1639908 ;source_file_1859.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..40] = [t:0..40] ;1)sentence:[e:46..238] = [t:46..238] ;2)section:[e:242..277] = [t:242..277] ;3)section:[e:281..364] = [t:281..364] ;4)sentence:[e:368..471] = [t:368..471] ;5)sentence:[e:472..643] = [t:472..643] ;6)sentence:[e:644..882] = [t:644..882] ;7)sentence:[e:883..981] = [t:883..981] ;8)section:[e:985..1029] = [t:985..1029] ;section 0 Span:0..40 ;J Chromatogr. 1992 Feb 28;593(1-2):25-8. (SEC (FRAG (NNP:[0..1] J) (NNP:[2..12] Chromatogr) (.:[12..13] .) (CD:[14..18] 1992) (NNP:[19..22] Feb) (CD:[23..28] 28;59) (CD:[28..29] 3) (NN:[29..30] -LRB-) (NN:[30..33] 1-2) (-RRB-:[33..34] -RRB-) (CD:[34..38] :25-) (CD:[38..40] 8.))) ;sentence 1 Span:46..238 ;High-performance liquid chromatographic analysis of FCE 24304 ;(6-methylenandrosta-1,4-diene-3,17-dione) and FCE 24928 ;(4-aminoandrosta-1,4,6-triene-3,17-dione), two new aromatase inhibitors. ;[98..107]:substance:"FCE 24304" ;[110..149]:substance:"6-methylenandrosta-1,4-diene-3,17-dione" ;[155..164]:substance:"FCE 24928" ;[167..206]:substance:"4-aminoandrosta-1,4,6-triene-3,17-dione" ;[217..226]:substance:"aromatase" ;[227..237]:substance:"inhibitors" (SENT (NP-HLN (NP (ADJP (JJ:[46..50] High) (HYPH:[50..51] -) (NN:[51..62] performance)) (JJ:[63..69] liquid) (JJ:[70..85] chromatographic) (NN:[86..94] analysis)) (PP (IN:[95..97] of) (NP (NP (NP (NP (NN:[98..101] FCE) (CD:[102..107] 24304)) (NP (-LRB-:[109..110] -LRB-) (NN:[110..149] 6-methylenandrosta-1,4-diene-3,17-dione) (-RRB-:[149..150] -RRB-))) (CC:[151..154] and) (NP (NP (NN:[155..158] FCE) (CD:[159..164] 24928)) (NP (-LRB-:[166..167] -LRB-) (NN:[167..206] 4-aminoandrosta-1,4,6-triene-3,17-dione) (-RRB-:[206..207] -RRB-)))) (,:[207..208] ,) (NP (CD:[209..212] two) (JJ:[213..216] new) (NN:[217..226] aromatase) (NNS:[227..237] inhibitors)))) (.:[237..238] .))) ;section 2 Span:242..277 ;Del Nero S, Di Somma M, Vigevani A. (SEC (FRAG (NN:[242..245] Del) (NNP:[246..250] Nero) (NNP:[251..252] S) (,:[252..253] ,) (NNP:[254..256] Di) (NNP:[257..262] Somma) (NNP:[263..265] M,) (NNP:[266..274] Vigevani) (NNP:[275..276] A) (.:[276..277] .))) ;section 3 Span:281..364 ;Department of Analytical Chemistry, R & D Farmitalia Carlo Erba Srl, Milan, ;Italy. (SEC (FRAG (NNP:[281..291] Department) (IN:[292..294] of) (NNP:[295..305] Analytical) (NNP:[306..315] Chemistry) (,:[315..316] ,) (NNP:[317..318] R) (CC:[319..320] &) (NNP:[321..322] D) (NNP:[323..333] Farmitalia) (NNP:[334..339] Carlo) (NNP:[340..344] Erba) (NNP:[345..348] Srl) (,:[348..349] ,) (NNP:[350..355] Milan) (,:[355..356] ,) (NNP:[358..363] Italy) (.:[363..364] .))) ;sentence 4 Span:368..471 ;The cytochrome P-450-dependent aromatase enzyme plays an important role in ;hormone-dependent diseases. ;[372..388]:cyp450:"cytochrome P-450" ;[399..415]:cyp450:"aromatase enzyme" ;[444..451]:substance:"hormone" (SENT (S (NP-SBJ (DT:[368..371] The) (ADJP (NML (NN:[372..382] cytochrome) (NN:[383..388] P-450)) (HYPH:[388..389] -) (JJ:[389..398] dependent)) (NN:[399..408] aromatase) (NN:[409..415] enzyme)) (VP (VBZ:[416..421] plays) (NP (DT:[422..424] an) (JJ:[425..434] important) (NN:[435..439] role)) (PP (IN:[440..442] in) (NP (ADJP (NN:[444..451] hormone) (HYPH:[451..452] -) (JJ:[452..461] dependent)) (NNS:[462..470] diseases)))) (.:[470..471] .))) ;sentence 5 Span:472..643 ;Many products that inhibit this type of enzyme were obtained: FCE 24304 (I) ;and FCE 24928 (II) proved to possess remarkable activity and are presently ;under development. ;[512..518]:substance:"enzyme" ;[535..544]:substance:"FCE 24304" ;[553..562]:substance:"FCE 24928" (SENT (S (S (NP-SBJ-2 (NP (JJ:[472..476] Many) (NNS:[477..485] products)) (SBAR (WHNP-1 (WDT:[486..490] that)) (S (NP-SBJ-1 (-NONE-:[490..490] *T*)) (VP (NP (VBP:[491..498] inhibit)) (NP (NP (DT:[499..503] this) (NN:[504..508] type)) (PP (IN:[509..511] of) (NP (NN:[512..518] enzyme)))))))) (VP (VBD:[519..523] were) (VP (VBN:[525..533] obtained) (NP-2 (-NONE-:[533..533] *))))) (::[533..534] :) (S (NP-SBJ-3 (NP (NP (NN:[535..538] FCE) (CD:[539..544] 24304)) (NP (LS:[545..548] -LRB-I-RRB-))) (CC:[549..552] and) (NP (NP (NN:[553..556] FCE) (CD:[557..562] 24928)) (NP (LS:[563..567] -LRB-II-RRB-)))) (VP (VP (VBD:[568..574] proved) (S (NP-SBJ-3 (-NONE-:[574..574] *)) (VP (TO:[575..577] to) (VP (VB:[578..585] possess) (NP (JJ:[586..596] remarkable) (NN:[597..605] activity)))))) (CC:[607..610] and) (VP (VBP:[611..614] are) (ADVP-TMP (RB:[615..624] presently)) (PP-PRD (IN:[625..630] under) (NP (NN:[631..642] development)))))) (.:[642..643] .))) ;sentence 6 Span:644..882 ;Compounds I and II and their synthetic intermediates are analyzed by means ;of a high-performance liquid chromatographic method, affording rapid and ;efficient separation, good resolution and identification of all the examined ;compounds. ;[644..655]:substance:"Compounds I" ;[644..653]...[660..662]:substance:"Compounds"..."II" ;[684..697]:substance:"intermediates" ;[872..881]:substance:"compounds" (SENT (S (NP-SBJ-3 (NP (NP (NML-2 (NNS:[644..653] Compounds)) (CD:[654..655] I)) (CC:[656..659] and) (NP (NML-2 (-NONE-:[659..659] *P*)) (CD:[660..662] II))) (CC:[663..666] and) (NP (PRP$:[667..672] their) (JJ:[673..682] synthetic) (NNS:[684..697] intermediates))) (VP (VBP:[698..701] are) (VP (VBN:[702..710] analyzed) (NP-3 (-NONE-:[710..710] *)) (PP-MNR (IN:[711..713] by) (NP (NP (NNS:[714..719] means)) (PP (IN:[720..722] of) (NP (DT:[723..724] a) (NP (JJ:[725..729] high) (HYPH:[729..730] -) (NN:[730..741] performance)) (JJ:[742..748] liquid) (JJ:[749..764] chromatographic) (NN:[766..772] method))))) (,:[772..773] ,) (S-ADV (NP-SBJ (-NONE-:[773..773] *)) (VP (VBG:[774..783] affording) (NP (NP (ADJP (JJ:[784..789] rapid) (CC:[790..793] and) (JJ:[794..803] efficient)) (NN:[804..814] separation)) (,:[814..815] ,) (NP (JJ:[816..820] good) (NN:[821..831] resolution)) (CC:[832..835] and) (NP (NP (NN:[837..851] identification)) (PP (IN:[852..854] of) (NP (PDT:[855..858] all) (DT:[859..862] the) (VBN:[863..871] examined) (NNS:[872..881] compounds))))))))) (.:[881..882] .))) ;sentence 7 Span:883..981 ;The linearity, specificity, sensitivity, precision and accuracy for the ;method are also provided. (SENT (S (NP-SBJ-1 (NP (DT:[883..886] The) (NN:[887..896] linearity) (,:[896..897] ,) (NN:[898..909] specificity) (,:[909..910] ,) (NN:[912..923] sensitivity) (,:[923..924] ,) (NN:[925..934] precision) (CC:[935..938] and) (NN:[939..947] accuracy)) (PP (IN:[948..951] for) (NP (DT:[952..955] the) (NN:[956..962] method)))) (VP (VBP:[963..966] are) (ADVP (RB:[967..971] also)) (VP (VBN:[972..980] provided) (NP-1 (-NONE-:[980..980] *)))) (.:[980..981] .))) ;section 8 Span:985..1029 ;PMID: 1639908 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[985..989] PMID) (::[989..990] :) (CD:[991..998] 1639908) (NN:[999..1000] -LSB-) (NNP:[1000..1006] PubMed) (::[1007..1008] -) (NN:[1009..1016] indexed) (IN:[1017..1020] for) (NNP:[1021..1029] MEDLINE-RSB-)))